576 related articles for article (PubMed ID: 9329609)
1. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
[TBL] [Abstract][Full Text] [Related]
2. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
3. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
5. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
[TBL] [Abstract][Full Text] [Related]
7. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
8. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.
Ferrero-Poüs M; Hacène K; Bouchet C; Le Doussal V; Tubiana-Hulin M; Spyratos F
Clin Cancer Res; 2000 Dec; 6(12):4745-54. PubMed ID: 11156229
[TBL] [Abstract][Full Text] [Related]
9. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
[TBL] [Abstract][Full Text] [Related]
10. Combined overexpression of c-erbB-2 protein and epidermal growth factor receptor (EGF-R) could be predictive of early and long-term outcome in human breast cancer: a pilot study.
Delarue JC; Terrier P; Terrier-Lacombe MJ; Mouriesse H; Gotteland M; May-Levin F
Bull Cancer; 1994 Dec; 81(12):1067-77. PubMed ID: 7742595
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of p53, bcl-2 and telomerase activity in Egyptian breast cancer patients.
Swellam M; Ismail M; Eissa S; Hamdy M; Mokhtar N
IUBMB Life; 2004 Aug; 56(8):483-90. PubMed ID: 15545228
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Surgery; 2003 Feb; 133(2):219-21. PubMed ID: 12605184
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer.
Iwase H; Itoh Y; Kuzushima T; Yamashita H; Iwata H; Toyama T; Hara Y; Kobayashi S
Cancer Detect Prev; 1997; 21(1):29-35. PubMed ID: 9043760
[TBL] [Abstract][Full Text] [Related]
14. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
[TBL] [Abstract][Full Text] [Related]
15. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
[TBL] [Abstract][Full Text] [Related]
16. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
[TBL] [Abstract][Full Text] [Related]
17. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
18. Tissue and serum c-erbB-2 and tissue EGFR in breast carcinoma: three years follow-up.
Mansour OA; Zekri AR; Harvey J; Teramoto Y; el-Ahmady O
Anticancer Res; 1997; 17(4B):3101-6. PubMed ID: 9329611
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients.
Liu ZB; Liu GY; Yang WT; Di GH; Lu JS; Shen KW; Shen ZZ; Shao ZM; Wu J
Oncol Rep; 2008 Oct; 20(4):987-94. PubMed ID: 18813844
[TBL] [Abstract][Full Text] [Related]
20. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
Aryandono T; Harijadi ; Ghozali A
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]